Join
Live feed
·
INSIDERFilingvia Quantisnow
Halozyme Therapeutics Inc. logo

Director Posard Matthew L. sold $2,046,581 worth of shares (18,996 units at $107.74) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 58,839 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
HALO· Halozyme Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HALO (Halozyme Therapeutics Inc.) and more on Quantisnow.